Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
Xiaofeng Jiang(Harvard University), F. Stephen Hodi(Dana-Farber Cancer Institute)
Cited by 132
Related Papers
Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
|JAMA Oncology|2016|750
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|592
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
|Journal of Clinical Oncology|2017|480
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
|Clinical Cancer Research|2012|470
Major Response to Imatinib Mesylate in <i>KIT</i>-Mutated Melanoma
|Journal of Clinical Oncology|2008|414